Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Endothelial Progenitor Cells: Hope Beyond Controversy

Author(s): E. Pasquier, S. Dias.

Abstract:

The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor cells (EPC) in adults and their putative vascular-promoting and/or vascular-healing properties, has generated some of the biggest fascination and debate in the broad field of vascular biology. The simple concept of a population of undifferentiated cells being able to generate new endothelial cells and the corresponding blood vessels in adults is both intriguing and, as seen in the last 10 years, controversial. Academic rivalry or pure scientific dispute has accompanied the research on EPC for some time. The major issues put forward by opposing groups of scientists regarding the identity and the role of EPCs as well as the optimal isolation and detection techniques are discussed in this review. The clinical relevance of EPCs and their potential applications in cancer treatments are also highlighted.

Keywords: Endothelial progenitor cells, cancer, tumor angiogenesis, postnatal vasculogenesis, stem cells, surrogate marker, hemangioblast-derived, pluripotent EPCs, EPCs, stromal-derived factor-1 (SDF-1), VE-cadherin, adventitial layer, Zampetaki, neovascularisation, Glioblastoma multiforme (n=56), chronic administration, Lewis lung carcinoma, treatment for stability, cyclophosphamide, gemcitabine, paclitaxel-based chemotherapy, Madlambayan, TAMs, Anti-angiogenic agents, HPC, CD, CXCR4, VDA

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 10
ISSUE: 8
Year: 2010
Page: [914 - 921]
Pages: 8
DOI: 10.2174/156800910793358041
Price: $58